Marseille Society – Mact Asso http://mact-asso.org/ Sun, 18 Sep 2022 11:14:21 +0000 en-US hourly 1 https://wordpress.org/?v=5.9.3 https://mact-asso.org/wp-content/uploads/2021/04/default-150x150.png Marseille Society – Mact Asso http://mact-asso.org/ 32 32 France-Atlanta Launches 13th Series of Annual Events, Fostering Transatlantic Connections in Culture, Science and Business https://mact-asso.org/france-atlanta-launches-13th-series-of-annual-events-fostering-transatlantic-connections-in-culture-science-and-business/ Fri, 16 Sep 2022 17:24:48 +0000 https://mact-asso.org/france-atlanta-launches-13th-series-of-annual-events-fostering-transatlantic-connections-in-culture-science-and-business/ By Hannah E. Jones The directory France-Atlanta The series of events is back for its 13th year, a six-week program focused on innovation, building transatlantic ties and exchanging knowledge in the fields of culture, humanitarian affairs, science and Business. The 2022 series of events runs from September 15 to November 3. Most events are free […]]]>

By Hannah E. Jones

The directory France-Atlanta The series of events is back for its 13th year, a six-week program focused on innovation, building transatlantic ties and exchanging knowledge in the fields of culture, humanitarian affairs, science and Business. The 2022 series of events runs from September 15 to November 3. Most events are free and everyone is welcome.

Since its inception, the series has attracted a total of 30,000 participants – ranging from experts, students and residents – engaging in a wide range of discussions and workshops on culture, science and business.

The series of events was co-founded and organized by the Consulate General of France in Atlanta and the Georgia Institute of Technology. France-Atlanta was created in 2010 to “breathe new life” into Franco-American relations, particularly in the Southeast, attracting more than 3,500 participants in the first year.

Rami Abi-Akl, scientific and technical attaché of the French Consulate, describes the collaboration between Atlanta and France as “important on several levels”. Between the city’s renowned universities, “Atlanta’s top talent” and mutual values, the Consulate team wishes to continue fostering a relationship that benefits transatlantic communities.

(Friche la Belle de Mai.) At a conference on October 5, French urban planner Alexandre Grondeau will encourage people to rethink the urban
spaces by giving more importance to the culture, politics, history and ecology of cities. (Photo courtesy of France-Atlanta.)

“The value of improving the lives of mankind is shared everywhere. But beyond that, Atlanta and France have common values ​​to be more inclusive and diverse,” Abi-Akl said. “These values ​​may not be shared with everyone but it’s very important here in Atlanta and it’s important in France.”

In many ways, Abi-Akl describes this partnership as an investment in our collective future.

“We always talk about the exchanges of today, but those of tomorrow depend a lot on science and technology. If we produce science and technology together, we build businesses and together we build the economy of tomorrow,” he said. “It means that in the world of tomorrow, we will be together. I think it’s important that we not only plan to be together now, but also in the future.

Each year, programming is tailored to Atlanta and French interests, and this year most events focus on current topics such as global health, supply chains, sustainability and urban culture.

In partnership with CITY CITÉ, France-Atlanta and the ELEVATE art festival, Marseille-based muralist Difuz is working on an artwork in downtown Atlanta. (Photo courtesy of France-Atlanta.)

One of the many questions asked: What is the role of culture in the development of our city? This year’s programming examines this issue through CITY CITYa program focused on urban issues and urbanism created by Villa Albertine.

Established in 2015, CITY CITÉ comes to Atlanta for the first time, hosting talks and arts programming highlighting the connections in culture, urban development and society between Atlanta and Marseille, France. Both cities are Southeast capitals with rich and complex histories and incubators for well-known rappers. The series of mini-events will host Marseille Wasteland Belle de Mai and a group of French urban planners, architects and artists who will examine the role of cultural infrastructure with their Atlanta counterparts.

The association will also welcome students from Georgia Tech, Emory University, a Canadian university and six European universities to AI and global health disparities. After six weeks of preparation, students are challenged to debate artificial intelligence and how we can ensure it is designed to help tackle health inequities, not increase health disparities .

There are also more hands-on events offered, like “make pandemics», an event where culture and science meet. The 100-minute documentary follows a woman who seeks to understand the links between human health and ecosystem health during this “epidemic of pandemics”.

As the first time the entire series has been offered in-person since the pandemic began, the team is especially excited for this year’s France-Atlanta series of events. Abi-Akl welcomes everyone and hopes attendees leave with new connections, ideas and a sense of being part of a new community.

“We want the community to know each other because when scientists talk to each other, new ideas emerge and collaborations emerge. Same for technology or business,” he said. “We also want them to feel welcome, like ‘I belong in this community and I can thrive [here].’ [Lastly, we want] that they come away with ideas because we don’t want passive participants, we want active participants.

If you want to learn more about the 13th Annual France-Atlanta Series of Events or want to see the full lineup list, Click here.

]]>
A great tennis compared to the “icons” Woods, Brady and Jordan by Bartoli https://mact-asso.org/a-great-tennis-compared-to-the-icons-woods-brady-and-jordan-by-bartoli/ Thu, 15 Sep 2022 21:45:45 +0000 https://mact-asso.org/a-great-tennis-compared-to-the-icons-woods-brady-and-jordan-by-bartoli/ Roger Federer ranks among sports greats such as Michael Jordan, Tiger Woods and Tom Brady. That was the message from 2013 Wimbledon champion Marion Bartoli, who hailed Federer after announcing that her participation in September’s Laver Cup would be her last in professional sport. The 41-year-old has won 20 Grand Slam titles during a legendary […]]]>

Roger Federer ranks among sports greats such as Michael Jordan, Tiger Woods and Tom Brady.

That was the message from 2013 Wimbledon champion Marion Bartoli, who hailed Federer after announcing that her participation in September’s Laver Cup would be her last in professional sport.

The 41-year-old has won 20 Grand Slam titles during a legendary 24-year career, only Novak Djokovic (21) and Rafael Nadal (22) can boast more Major crowns in tennis male.

Federer has also won more men’s singles main draw matches at Grand Slam tournaments than any other player in the Open Era (369), leaving behind a magnificent legacy as he prepares to step off the court.

Bartoli has retired herself, having ended her career following a failed comeback from injury in 2018, and asked Stats Perform if Federer was a GOAT – the greatest of all time – Bartoli said : “Yes, he is really in there – Absolutely.

“Michael Jordan, Kobe Bryant, LeBron James, Tiger Woods, Tom Brady, these are people who transcend their sport, they are icons.

“You go to the street, you say Roger Federer. I’m in Dubai right now [and if] you say “Roger Federer”, everyone would know who he is. And the same for LeBron and Michael Jordan.

“When you transcend your sport and become an icon and everyone knows who you are, that’s when you know you were one of the greatest of all time in all of sports.

“Same for Serena [Williams], you can also put Novak and Rafa there. But it’s just that amount of fame and that amount of inspiration [the next] generation.”

After spending 237 straight weeks at No. 1, Federer holds the record for the longest such streak in men’s singles history after a four-and-a-half-year stint at the top.

Federer has also been in the top 10 of the men’s singles rankings for 750 weeks, the highest number for a male player since the rankings were first published in 1973.

Regardless of Federer trailing Djokovic and Nadal for the Grand Slam titles, Bartoli believes the Swiss remains the best of the trio due to his elegant style of play.

“It depends a lot on your taste. If you like beautiful, elegant and flowing tennis, you have to go for Roger Federer,” she added.

“Now obviously with Novak having 21 and Rafa having 22 in Grand Slams, if we just talk about the numbers you have two players above him.

“But I think it’s really a debate because it depends on what style of play you like and, having said that, I love seeing Novak play and win.

“I absolutely loved seeing Rafa win again at Roland Garros this year, I think it was one of the most incredible sporting feats you can ever witness.

“But in terms of his style of play and how he revolutionized tennis, I think Roger was the first. And then they pushed themselves to new heights and I think that was really special to see. “

While many youngsters seek to emulate Federer, Djokovic and Nadal, Bartoli also highlighted the importance of Pete Sampras and Andre Agassi.

“You can tell how much of an impact a player has [has] when you see a new generation trying to copy your style. I think Pete Sampras had that impact as well as Andre Agassi on the generation of Roger, Rafa and Novak,” she continued.

“Roger had that impact on the new generation with Carlos Alcaraz. That’s why I say he was really the first to take the game to another level because he brought that dimension of his forehand as he was really almost able to play the ball where he wanted.

“I always remember this sentence from André Agassi, when he started to play against Roger saying: ‘well, I never felt against anyone that I had to play on a square of 20 centimeters because that it’s the only safe place I can play, which is deep behind Roger’s back. If I play anywhere, he’ll take the game away from me.” [Federer] was the first to [do that] then obviously Rafa and Novak came along and sought to change that and they pushed themselves to new heights.

“When you have the pinnacle of the 2008 Wimbledon final and all those matches between them, that was just beyond epic for me.”

]]>
Presents Positive Safety and Efficacy Data from Completed Phase 1 Dose Escalation Cohort… | Your money https://mact-asso.org/presents-positive-safety-and-efficacy-data-from-completed-phase-1-dose-escalation-cohort-your-money/ Sat, 10 Sep 2022 13:15:00 +0000 https://mact-asso.org/presents-positive-safety-and-efficacy-data-from-completed-phase-1-dose-escalation-cohort-your-money/ Broad antitumor immune responses and demonstration of durable disease control in patients with solid tumors who had previously failed one or more checkpoint inhibitor regimens, over a range of doses of ICT01 in combination with pembrolizumabICT01 demonstrated a favorable and consistent safety and tolerability profile without dose-limiting toxicities in combination, in line with the results […]]]>

Broad antitumor immune responses and demonstration of durable disease control in patients with solid tumors who had previously failed one or more checkpoint inhibitor regimens, over a range of doses of ICT01 in combination with pembrolizumabICT01 demonstrated a favorable and consistent safety and tolerability profile without dose-limiting toxicities in combination, in line with the results of monotherapy

ImCheck Therapeutics today presented promising safety and patient response data from the full dose-escalation combination cohort of its ongoing EVICTION clinical trial during an oral session at the European Society of Medical Oncology (ESMO) which is currently being held in Paris, France. EVICTION is an open-label phase I/IIa study evaluating ImCheck’s lead antibody ICT01 as monotherapy in solid tumors and hematological cancers, and in combination with pembrolizumab in solid tumors.

Results from the combined Phase I dose-escalation cohorts (n=40 across 6 dose levels) demonstrated that treatment with ICT01 plus pembrolizumab induced disease control in 42% of melanomas (5/12), 22 % of non-small cell lungs (4/18), 22% of patients with bladder cancer (2/9), and in 1 patient with head and neck squamous cell carcinoma (HNSCC), (1/1) according to RECIST1.1 criteria. All treated patients had previously failed at least one checkpoint inhibitor (CPI) regimen, highlighting the potential of ICT01 combination therapy as a new option for relapsed/refractory patients after CPI treatment. , which remains a significant unmet medical need. Two partial responses were achieved in melanoma patients who achieved follow-up beyond 6 and 16 months, with the latter patient also achieving durable complete regression of a brain metastasis from 6 months. General antitumor response data suggest that higher baseline circulating γ9δ2 T cell levels are correlated with better treatment outcomes. This supports the planned patient enrichment strategy using a lower baseline γ9δ2 T cell count, compared to ICT01 monotherapy, for eligibility in the upcoming phase IIa combination groups of patients with IPC-refractory melanoma , chemotherapy-resistant bladder cancer, or IPC-refractory HNSCC.

“The data presented today demonstrate that the complementary mechanisms of action of ICT01 and pembrolizuma alter the tumor microenvironment to generate clinical responses against multiple IPC-resistant solid tumors,” commented Paul Frohna, MD, PhD, Medical Director at ImCheck Therapeutics. “It is encouraging to see a continued good safety profile for ICT01 under the combination in addition to the robust activation of γ9δ2T cells that promote tumor infiltration of CD8 and NK cells, which can be fully released to attack tumors. cancer cells by concomitant blockade of PD-1.”

Pierre d’Epenoux, Chief Executive Officer of ImCheck Therapeutics, added: “With these positive data, we further confirm the potential of ICT01 as an innovative and differentiated therapeutic approach for a large population of cancer patients. . We are confident that we have achieved our goals for the first part of the EVICTION trial, both in monotherapy the expansion is already underway and in combination with pembrolizumab.

The oral presentation, titled “The combination of ICT01, a γ9δ2 T-cell activating mAb, plus pembrolizumab induces a broad antitumor immune response and disease control in patients with CPI-failure melanoma, NSCLC, and prostate cancer. bladder: EVICTION trial”, was given by Dr Stéphane Champiat, principal investigator of the EVICTION study at the Gustave Roussy Cancer Center, Paris, France. The data was presented during the Experimental Immunotherapy session from 2:45 p.m. to 4:15 p.m. CEST on Saturday, September 10, 2022.

***

About the EVICTION Trial EVICTION is a first-in-man, dose-escalating (Part 1) and cohort-expanding (Part 2) clinical trial of ICT01 in patients with various advanced solid or hematologic cancers, relapsed or refractory, who have exhausted standard treatment options. Part 1 is a collaborative trial designed to characterize the preliminary safety, tolerability and pharmacodynamic activity of ICT01 as monotherapy (group A: solid tumors; group B: hematological tumors) and in combination with pembrolizumab (group C: solid tumors). Group A includes patients with bladder, breast, colorectal, gastric, melanoma, ovary, prostate and pancreatic cancer, Group B includes acute myeloid leukemia, acute lymphoid leukemia, follicular lymphoma and patients with diffuse large B-cell lymphoma, and group C includes bladder, patients with head and neck squamous cell carcinoma, melanoma and non-small cell lung cancer. Basket trials are a clinical trial design that allows rapid testing of new drugs in a range of indications, providing initial data on multiple endpoints that can contribute to an accelerated development timeline. Part 2 of the trial is a Phase II cohort expansion study in selected indications, both as monotherapy and in combination. The first indications selected for the Phase II monotherapy expansion cohorts are relapsed/refractory ovarian cancer and metastatic castration-resistant prostate cancer. For more information about the EVICTION trial, visit clinicaltrials.gov (NCT04243499). A second clinical trial, EVICTION-2, evaluating the combination of ICT01 and low-dose subcutaneous IL-2 to selectively increase the number of γ9δ2 T cells in patients with solid tumors (prostate cancer, pancreas, ovary or colorectal) is also in progress ( NCT05307874).

About ICT01 ICT01 is a humanized anti-BTN3A (also known as CD277) monoclonal antibody that selectively activates γ9δ2 T cells, which are part of the innate immune system responsible for immunosurveillance of malignancies and infections. The 3 isoforms of BTN3A targeted by ICT01 are overexpressed on a number of solid tumors (eg bladder, colorectal, melanoma, ovary, pancreatic, lung) and hematological cancers (eg leukemia & lymphoma) and also expressed on the surface of the innate (eg, γδ T cells and NK cells) and adaptive immune cells (T cells and B cells). BTN3A is essential for the activation of the anti-tumor immune response of γ9δ2 T cells.

As demonstrated in EVICTION data presented at recent AACR, EMSO, and SITC conferences, ICT01 selectively activates circulating γ9δ2 T cells, resulting in migration of γ9δ2 T cells out of circulation and into target tissues (e.g., tumors ), while also activating the tumor. resident γ9δ2 T cells to directly kill malignant cells, which is accompanied by the secretion of two key inflammatory cytokines, IFNγ and TNFα, which contribute to the expansion of the anti-tumor immune response. ICT01 has been shown to have anti-tumor activity against a range of cancers in in vitro and in vivo tumor models.

About IMCHECK THERAPEUTICS

ImCheck Therapeutics designs and develops a new generation of immunotherapeutic antibodies targeting butyrophilins, a new superfamily of immunomodulators.

As demonstrated by the leading clinical-stage program ICT01, which has a mechanism of action to simultaneously modulate innate and adaptive immunity, ImCheck’s “first-in-class” activating antibodies may be able to deliver results clinical superiority over first-generation immune checkpoint inhibitor antibodies and, when used in combination, to overcome resistance to this group of agents. Additionally, ImCheck’s antagonist antibodies are being evaluated as potential treatments for a range of autoimmune diseases.

Co-founder of the Marseille Immunopole cluster, ImCheck benefits from the support of Pr Daniel Olive (INSERM, CNRS, Institut Paoli Calmettes, Aix-Marseille University), world leader in research on γ9δ2 T lymphocytes and butyrophilins; the experience of an expert management team; and the commitment of leading US and European investors.

For more information: https://www.imchecktherapeutics.com/ and @ImCheckThx

Press contacts

Trophic Communications US and EU Gretchen Schweitzer +49 (0) 172 861 8540 imcheck@trophic.eu

France ATCG PARTNERS Céline Voisin +33 (0)9 81 87 46 72 / +33 (0)6 62 12 53 39 imcheck@atcg-partners.com

Attachments

PR in EnglishPresentation to ESMO

]]>
GRAIL to Present Final Multi-Cancer Early Detection Data from the PATHFINDER Interventional Study at ESMO 2022 https://mact-asso.org/grail-to-present-final-multi-cancer-early-detection-data-from-the-pathfinder-interventional-study-at-esmo-2022/ Thu, 08 Sep 2022 22:05:00 +0000 https://mact-asso.org/grail-to-present-final-multi-cancer-early-detection-data-from-the-pathfinder-interventional-study-at-esmo-2022/ MENLO PARK, Calif.–(BUSINESS WIRE)–GRAIL, LLC, a healthcare company whose mission is to find cancer early when it can be cured, today announced that final results from the PATHFINDER interventional study will be presented at Congress. 2022 from the European Society of Medical Oncology (ESMO) in Paris. PATHFINDER data evaluating the Galleri® The Multi-Cancer Early Detection […]]]>

MENLO PARK, Calif.–(BUSINESS WIRE)–GRAIL, LLC, a healthcare company whose mission is to find cancer early when it can be cured, today announced that final results from the PATHFINDER interventional study will be presented at Congress. 2022 from the European Society of Medical Oncology (ESMO) in Paris. PATHFINDER data evaluating the Galleri® The Multi-Cancer Early Detection (MCED) blood test will be shared in a communications session on September 11. Participant-reported outcomes will also be presented, including satisfaction with MCED testing, continued adherence to screening standards of care, and information related to participants’ anxiety and distress. Interim results from the PATHFINDER study were presented at the 2021 Annual Meeting of the American Society of Clinical Oncology (ASCO).

The PATHFINDER single-arm interventional study was designed to assess clinical care pathways following a Galleri test result “cancer signal detected”, measure the time to diagnostic resolution (primary endpoint), and assess the implementation and performance of Galleri in a clinical setting. care setting.

Despite 50 years of war on cancer, cancer is fast becoming the world’s number one killer, largely because most cancers are diagnosed too late. Although current screening tests save lives, they are not enough and the status quo in cancer screening is simply unacceptable. In the United States, we only routinely screen for five cancers, but most cancer deaths are from cancers we don’t screen for. Our current approach using decades-old technology with suboptimal adherence simply does not find enough cancers in the population. We need to move from just finding individual cancers to finding people for many cancers,” said Josh Ofman, MD, MSHS, president of GRAIL. “We are excited to share final results from PATHFINDER, which provide important insights into the feasibility of our first-of-its-kind MCED technology, clinical care pathways following a “cancer signal detected” result, and Galleri’s potential to detect more cancers in their early stages in addition to standard screenings.

The PATHFINDER study recruited 6,662 people aged 50 or older, an age group at high risk for cancer, but with no suspicion of active cancer. Participants were enrolled at 11 sites, including the Cleveland Clinic, Dana-Farber Cancer Institute, Mayo Clinic, Oregon Health & Science University, Sutter Health and the US Oncology Network. Results will be presented from both an earlier version of Galleri (MCED-E) and a predefined retrospective analysis evaluating the current version of the Galleri test (MCED-Scr) using banked blood samples.

Selected GRAIL presentations at ESMO include:

A Prospective Study of a Blood Test for the Early Detection of Multiple Cancers (Presentation #903O)

Session type: offered communication session

Date/Time: Sunday, September 11, 4:30 p.m. – 4:40 p.m. CEST (10:30 a.m. – 10:40 a.m. EST)

Location: 7.3.O – Orléans Auditorium

Speaker: Deborah Schrag, MD, MPH, Chair of the Department of Medicine at Memorial Sloan Kettering Cancer Center (MSK)

Assessing Anxiety, Distress, and Satisfaction with an Early Detection Test for Multiple Cancers (Presentation #908P)

Session Type: Electronic Poster

Date/Time: Sunday, September 11

Speaker: Deborah Schrag, MD, MPH, Chair of the Department of Medicine at Memorial Sloan Kettering Cancer Center (MSK)

Time to Diagnosis in Cancer Patients in the United States (Presentation #1318MO)

Type of session: Mini oral session

Date/Time: Monday, September 12, 5:10 p.m. – 5:15 p.m. CEST (11:10 a.m. – 11:15 a.m. EST)

Location: 7.3.M – Marseille Auditorium

Speaker: Matthew Gitlin, Doctor of Pharmacy, BluePath Solutions

Abstracts are available on the ESMO Congress 2022 website. Additional data from the PATHFINDER study will be presented at the congress.

About GRAIL’s MCED Clinical Development Program

The Galleri clinical development program consists of studies that collectively include more than 335,000 participants – and what are believed to be the largest linked datasets of genomic and clinical data in the field of cancer. GRAIL’s program includes the CCGA Core Development and Validation Study, the PATHFINDER and PATHFINDER 2 Interventional Studies, the NHS-Galleri Randomized Controlled Clinical Study, the STRIVE and SUMMIT Observational Studies, and the REFLECTION Real-World Registry. . The largest of these, the NHS-Galleri trial, recruited 140,000 participants with the primary aim of a reduction in late-stage cancer diagnoses, seen as a necessary precondition for a reduction in mortality .

About GRAIL

GRAIL is a healthcare company whose mission is to find cancer early, when it can be cured. GRAIL is focused on alleviating the global cancer burden by developing pioneering technology to detect and identify multiple types of deadly cancers early. The company uses the power of next-generation sequencing, population-scale clinical studies, and cutting-edge computing and data science to improve scientific understanding of cancer biology and develop its system early detection of multiple cancers. test. GRAIL is headquartered in Menlo Park, CA, with offices in Washington, DC, North Carolina, and the United Kingdom. GRAIL, LLC, is a subsidiary of Illumina, Inc. (NASDAQ: ILMN) currently held separately from Illumina Inc. pursuant to the European Commission’s Interim Measures Order dated October 29, 2021.

For more information, visit grail.com.

About Galléri®

The earlier the cancer is detected, the higher the chances of success. Galleri’s Multi-Cancer Early Detection Test can detect signals in more than 50 types of cancer, as defined by the American Joint Committee on Cancer Staging Manual, through a routine blood draw. When a cancer signal is detected, the Galleri test predicts the origin of the cancer signal, or the location of the cancer in the body, with high accuracy to help guide the next steps in diagnosis. The Galleri test requires a prescription from a licensed healthcare provider and should be used in addition to recommended cancer screenings such as mammography, colonoscopy, prostate-specific antigen (PSA) testing, or cancer screening of the cervix. It is intended for use in people at high risk of cancer, such as people aged 50 or over.

All cells – cancerous and healthy – release DNA, called cell-free DNA, into the bloodstream. One of the “characteristics of cancer” is the addition of methyl groups to DNA. It does not alter the DNA code but can alter gene expression. Methylation patterns on tumor-derived cell-free DNA carry cancer-specific signals and are therefore very useful in detecting cancer and determining its origin. Galleri uses next-generation sequencing and machine learning algorithms to analyze these cell-free DNA methylation patterns in blood.

For more information about Galleri, visit galleryi.com.

Important Galleri Safety Information

Galleri’s test is recommended for use in adults at high risk for cancer, such as those age 50 or older. The Galleri test does not detect all cancers and should be used in addition to routine cancer screening tests recommended by a healthcare professional. Galleri is intended to detect cancer signals and predict where the cancer signal is located in the body. The use of Galleri is not recommended in people who are pregnant, aged 21 or younger or who are undergoing active cancer treatment.

Results should be interpreted by a healthcare professional in the context of medical history, clinical signs and symptoms. A “No Cancer Signal Detected” test result does not rule out cancer. A “Cancer Signal Detected” test result requires confirmatory diagnostic evaluation by medically established procedures (eg, imaging) to confirm cancer.

If the cancer is not confirmed by additional tests, it could mean that there is no cancer or that the tests were insufficient to detect the cancer, especially because the cancer is located in another part of the body . False positive (cancer signal detected in the absence of cancer) and false negative (cancer signal not detected in the absence of cancer) test results occur. Rx only.

Lab/Test Information

GRAIL’s clinical laboratory is certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA) and accredited by the College of American Pathologists. The Galleri test was developed and its performance characteristics determined by GRAIL. The Galleri test has not been cleared or approved by the United States Food and Drug Administration. GRAIL’s clinical laboratory is regulated by the CLIA to perform high complexity testing. The Galleri test is intended for clinical purposes.

]]>
Innate Pharma to Present Lacutamab PTCL Phase 1b Design and ANKET™ Platform at ESMO 2022 | Company https://mact-asso.org/innate-pharma-to-present-lacutamab-ptcl-phase-1b-design-and-anket-platform-at-esmo-2022-company/ Mon, 05 Sep 2022 05:02:06 +0000 https://mact-asso.org/innate-pharma-to-present-lacutamab-ptcl-phase-1b-design-and-anket-platform-at-esmo-2022-company/ MARSEILLE, France–(BUSINESS WIRE)–Sept. 5, 2022– Regulatory news: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“ Innate “or the” Company ”) announced today that the following presentations will be presented at the 2022 Annual Meeting of ESMO (European Society for Medical Oncology) to be held September 9-13, 2022, in Paris, France. A Multicenter Phase Ib […]]]>

MARSEILLE, France–(BUSINESS WIRE)–Sept. 5, 2022–

Regulatory news:

Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“ Innate “or the” Company ”) announced today that the following presentations will be presented at the 2022 Annual Meeting of ESMO (European Society for Medical Oncology) to be held September 9-13, 2022, in Paris, France.

  • A Multicenter Phase Ib Trial Evaluating the Safety and Efficacy of Lacutamab in Patients With Relapsed or Refractory KIR3DL2-Expressing Peripheral T-Cell Lymphoma
    – Abstract number: 647TiP
    – Session type: Trial in progress poster
    – Session title: Malignant hematology
    – Date of the session: Sunday, September 11, 2022
    – Presenter: Marianna Muller, MD, PharmD, Director of Clinical Development at Innate Pharma
  • Oral Presentation: Multispecific Antibody Design: ANKET for Antigen-Specific Activation of NK Cells
    – Type of session: Special session
    – Session Title: Next Frontiers in Drug Discovery
    – Date and time: Monday, September 12, 2022 from 9:05 a.m. to 9:20 a.m. CEST
    – Location: 7.3.U – Urval Auditorium
    – Speaker: Eric Vivier, DVM, PhD, Scientific Director of Innate Pharma
  • Oral presentation: Study of neoadjuvant durvalumab (D) platform alone or in combination with new agents in patients (pts) with resectable early-stage non-small cell lung cancer (NSCLC): pharmacodynamic correlates and dynamics of circulating tumor DNA (ctDNA) in the NeoCOAST study [AstraZeneca-sponsored]
    – Presentation #929MO
    – Type of session: Mini oral session
    – Session title: Non-metastatic NSCLC and other thoracic malignancies
    – Date and time: Monday, September 12, 2022 at 3:15 p.m. CEST
    – Location: 7.3.O – Orléans Auditorium
    – Presenter: Jonathan Spicer (Montreal, Canada)

The poster and the presentations will be available on the Publications section of innate-pharma.com after the presentation.

About lacutamab:

Lacutamab (IPH4102) is a first-in-class anti-KIR3DL2 cytotoxicity-inducing humanized antibody currently in clinical trials for the treatment of cutaneous T-cell lymphoma (CTCL), an orphan disease, and T-cell lymphoma T device (PTCL). Rare cutaneous T-cell lymphomas have a poor prognosis with few effective and safe treatment options in advanced stages.

KIR3DL2 is an inhibitory receptor of the KIR family, expressed by approximately 65% ​​of patients in all CTCL subtypes and expressed by up to 90% of patients with certain aggressive CTCL subtypes, in particular Sézary. It is expressed by up to 50% of patients with mycosis fungoides and peripheral T-cell lymphoma (PTCL). It has a restricted expression on normal tissues.

About ANKET™:

ANKET™ ( A antibody-based NK cell E engage J herapeutics) is Innate’s proprietary platform for the development of next-generation multispecific natural killer (NK) cell engagers to treat certain types of cancer.

This versatile and adaptive technology creates an entirely new class of molecules to induce synthetic immunity against cancer. It harnesses the benefits of harnessing NK cell effector functions against cancer cells and also provides targeted proliferation and activation signals to NK cells.

Our latest innovation, the tetra-specific ANKET molecule, is the first NK cell engagement technology to engage activating receptors (NKp46 and CD16), tumor antigen and interleukin-2 receptor (via a variant of the IL-2, IL-2v) via a single molecule.

About monalizumab:

Monalizumab is a potentially first-in-class immune checkpoint inhibitor targeting NKG2A receptors expressed on tumor-infiltrating CD8+ cytotoxic T cells and NK cells.

NKG2A is an inhibitory checkpoint receptor for HLA-E. By expressing HLA-E, cancer cells can protect themselves against destruction by NKG2A+ immune cells. HLA-E is frequently overexpressed in cancer cells of many solid tumors and hematological malignancies. Monalizumab may restore a broad NK and T cell-mediated anti-tumor response, and may increase the cytotoxic potential of other therapeutic antibodies 1.

Ongoing development of monalizumab focuses on studying monalizumab in various combination strategies in different malignancies, including, in early-onset lung cancer, the Phase 3 PACIFIC-9 study in adults with locally advanced (stage III), unresectable NSCLC who did not progress after concurrent platinum-based chemoradiotherapy and the NeoCOAST-2 phase 2 study in the early neoadjuvant setting of NSCLC.

About Innate Pharma:

Innate Pharma SA is a clinical-stage oncology-focused global biotechnology company dedicated to improving treatments and clinical outcomes for patients through antibody therapeutics that harness the immune system to fight cancer.

Innate Pharma’s large antibody portfolio includes several potentially first-in-class clinical and preclinical candidates in cancers with high unmet medical need.

Innate is a pioneer in understanding Natural Killer cell biology and has expanded its expertise in tumor microenvironment and tumor antigens, as well as antibody engineering. This innovative approach has resulted in a diversified proprietary portfolio and major alliances with leaders in the biopharmaceutical industry, including Bristol-Myers Squibb, Novo Nordisk A/S, Sanofi, and a multi-product collaboration with AstraZeneca.

Based in Marseille, France, with a US office in Rockville, MD, Innate Pharma is listed on Euronext Paris and Nasdaq in the United States.

Learn more about Innate Pharma at www.innate-pharma.com

Information on Innate Pharma shares:

ISIN code

FR0010331421

Stock code

Euronext: IPH Nasdaq: IPHA

LEI

9695002Y8420ZB8HJE29

Disclaimer of forward-looking information and risk factors:

This press release contains certain forward-looking statements, including those within the meaning of the Private Securities Litigation Reform Act of 1995. The use of certain words, including “believe”, “potential”, “expect” and ” will” and similar expressions, is intended to identify forward-looking statements. Although the company believes that its expectations are based on reasonable assumptions, these forward-looking statements are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those anticipated. These risks and uncertainties include, among others, uncertainties inherent in research and development, including those relating to the safety, progress and results of its ongoing and planned clinical trials and preclinical studies, the review and the approval by regulatory authorities of its product candidates, the Company’s commercialization efforts and the Company’s continued ability to raise capital to finance its development. For a further discussion of the risks and uncertainties that could cause the company’s actual results, financial condition, performance or achievements to differ from those contained in the forward-looking statements, please refer to the Risk Factors section. (“Risk Factors”) of the Universal Registration Document filed with the Autorité des Marchés Financiers (“AMF”), available on the AMF’s website http://www.amf-france.org or on Innate Pharma’s website, and public filings and reports filed with the U.S. Securities and Exchange Commission (“SEC”), including the Company’s Annual Report on Form 20-F for the fiscal year ended December 31 2021, and subsequent filings and reports filed with the AMF or the SEC, or otherwise made public, by the Company.

This press release and the information it contains do not constitute an offer to sell or a solicitation of an offer to buy or subscribe for shares of Innate Pharma in any country whatsoever.

1 André et al, Cell 2018

See the source version on businesswire.com: https://www.businesswire.com/news/home/20220904005030/en/

CONTACT: For more information:Investors and MediaInnate Pharma

Henry Wheeler

Such. : +33 (0)4 84 90 32 88

Henry.wheeler@innate-pharma.frATCG Press

Delphine Lens (France)

Such. : +33 (0)9 81 87 46 72

innate-pharma@atcg-partners.com

KEYWORD: EUROPE UNITED STATES NORTH AMERICA FRANCE

SECTOR KEYWORD: BIOTECHNOLOGY HEALTH PHARMACEUTICALS CLINICAL TRIALS ONCOLOGY

SOURCE: Innate Pharma SA

Copyright BusinessWire 2022.

PUBLISHED: 05/09/2022 01:00/DISC: 05/09/2022 01:02

http://www.businesswire.com/news/home/20220904005030/en

]]>
Clubs fined by UEFA for FFP breaches https://mact-asso.org/clubs-fined-by-uefa-for-ffp-breaches/ Sat, 03 Sep 2022 15:34:43 +0000 https://mact-asso.org/clubs-fined-by-uefa-for-ffp-breaches/ LAUSANNE: Paris Saint-Germain, Inter Milan and Juventus are among the clubs that were fined by UEFA on Friday for violating Financial Fair Play (FFP) rules, the football governing body said European. French champions PSG owned by Qatar received the biggest fine of 10 million euros ($10 million) while Roma, AC Milan, Besiktas, Marseille and Monaco […]]]>

LAUSANNE:

Paris Saint-Germain, Inter Milan and Juventus are among the clubs that were fined by UEFA on Friday for violating Financial Fair Play (FFP) rules, the football governing body said European.

French champions PSG owned by Qatar received the biggest fine of 10 million euros ($10 million) while Roma, AC Milan, Besiktas, Marseille and Monaco were also punished.

The fines were imposed after an analysis of the financial years from 2018 to 2022 by UEFA’s Club Financial Control Body found they had not all met the ‘break-even requirement’ .

Roma are to pay five million euros and Inter four million euros, while Juventus were fined 3.5 million euros and Milan two million euros.

Besiktas must pay 600,000 euros. The lowest fines went to Marseille and Monaco, which must pay 300,000 euros each.

However, UEFA said clubs were only asked to pay 15% of the total agreed “financial contributions”.

Therefore, PSG’s fine could rise to 65 million euros if they don’t respect the agreement reached with UEFA for the next three years, while Roma’s fine could reach 35 million. euros.

Most clubs have agreed to three-year settlement periods, but Roma and Inter have both chosen four years to meet UEFA’s targets, meaning they cannot sign new players for European competition this season.

“Under the three-year settlement agreement, the clubs agree to abide by the football earnings rule during the 2025/26 season,” UEFA said.

“They undertake to achieve intermediate annual objectives, and to apply conditional financial and sporting measures if these objectives are not achieved.”

UEFA announced earlier this year that it was phasing out its existing Financial Fair Play rules, which were introduced in 2010 and allowed clubs to declare losses of no more than €30m over a period. of three years.

However, fiscal years 2020 and 2021 were assessed as one unified period due to the impact of the pandemic.

The FFP is being replaced by new licensing and ‘future-proofing’ regulations which will allow clubs to declare losses of €60m over three years, and the figure allowed can even be as high as €90m for a club “in good financial health”.

PSG have been targeted by UEFA over FFP in the past. The club were cleared in 2018 following an investigation triggered by the €400m payment to buy Neymar and Kylian Mbappe in August 2017.

Before that, in 2014, PSG were fined 60 million euros for breaching the rules, although two-thirds of that amount was suspended.

PSG president Nasser al-Khelaifi, president of the powerful European Club Association, also sits on the UEFA executive committee.

]]>
Dark commerce — The Hague needs Gazprom — Greening Walloon urban transport – POLITICO https://mact-asso.org/dark-commerce-the-hague-needs-gazprom-greening-walloon-urban-transport-politico/ Thu, 01 Sep 2022 13:03:14 +0000 https://mact-asso.org/dark-commerce-the-hague-needs-gazprom-greening-walloon-urban-transport-politico/ Press play to listen to this article A conversation about what makes a city livable. By AITOR HERNANDEZ-MORALES Send tips here | Tweeter @aitorehm | View in your browser Happy Thursday, city ​​lovers, and welcome to POLITICO’s Living Cities project. The hunger for fast delivery in the age of the pandemic has led to the […]]]>

Press play to listen to this article

A conversation about what makes a city livable.

By AITOR HERNANDEZ-MORALES

Send tips here | Tweeter @aitorehm | View in your browser

Happy Thursday, city ​​lovers, and welcome to POLITICO’s Living Cities project.

The hunger for fast delivery in the age of the pandemic has led to the rise of so-called ‘dark’ commerce – the warehouses and kitchens from which delivery people come in and out to pick up and deliver goods – across Europe .

While dark stores give consumers one-click access to takeout and groceries, they also disrupt a neighborhood’s traffic flows, prompting complaints from residents who are fed up with scooters loud and reckless driving.

We’ll dig into the issue — and the political battle brewing over black trade in Paris — after the jump.

METRO BRIEFING

‘DARK’ DISTURBANCES: Few of us can claim to have never ordered takeout at the end of a long day, or to break the monotony of home cooking. Delivery apps make things easier, after all. But this convenience has a downside. These fast shipments rely on supposedly dark stores and kitchens dotted around the city, and for those living nearby, the 24/7 delivery schedule has become a major noise and traffic nuisance.

Public pressure: In places like Barcelona’s Les Corts district, residents demanded that leaders take action to curb the constant comings and goings of noisy delivery scooters. In the Spanish city of Segovia, police arrested four drivers who were driving without a license or on sidewalks and other pedestrian areas while delivering food.

image

Residents living near ‘dark’ shops have called for action to curb disruptive delivery scooter traffic | Fabrice Coffrini/AFP via Getty Images

French Fracasses: The question of regulating dark commerce has become a hot topic in France, after the leak of a proposed government decree that appeared to designate all locations with a click-and-collect counter as retailers rather than wholesalers. This would “de facto legalize” dark stores nationwide, according to Paris deputy mayor Emmanuel Grégoire. The draft text sparked outrage and prompted the mayors of Bordeaux, Lille, Marseille, Lyon, Strasbourg, Paris and other cities to demand regulatory tools for cities to crack down on all dark shops and kitchens, not just those without click-and-collect. counters.

Just testing the waters? A French government spokesperson said cities will eventually have the power to regulate such establishments as they see fit and that the draft decree is simply intended to legally define dark shops.

Too little, too late? Even as local and national governments come up with new rules to limit the impact of dark stores, some say it’s already too late. As with AirBnb and e-scooters, the disruption happened too quickly to regulate. The heyday of delivery apps can also be short-lived. The pandemic-era delivery boom is largely over and start-ups are slowing down rather than continuing to grow.

My colleagues Peter O’Brien and Pieter Haeck have more here.

CITY HIGHLIGHTS

image

The Hague seeks controversial exemption | Aitor Hernandez-Morales

BREAKING UP IS HARD: The Hague is asking for a temporary exemption from EU sanctions against Russia, saying it is struggling to find a new gas supplier to replace its existing deal with Russian energy giant Gazprom. Current EU sanctions force governments and public bodies to terminate all existing contracts with Russian companies by October 10. be the one to ask for more time: a number of Dutch municipalities also have energy contracts with Gazprom.

EARLY RETREAT: Nobody said it would be easy to get Brussels to give up the car, but the speed with which some municipalities are abandoning measures to reduce car use is surprising. This week, the municipal authorities of Molenbeek announced that they were ending the traffic pilot project in response to complaints from local traders. They promised to come back with a new plan in three months.

NEW SEC-GEN EUROCITIES: The former vice-president of the Nantes metropolis André Sobczak this week took the helm of Eurocities, the network of more than 200 cities which campaigns for a better quality of life in urban areas. He succeeds Anna Lisa Boni, who resigned last year to become deputy mayor of Bologna. Among his priorities, he cites the training of the next generation of municipal leaders and the adaptation of cities to climate change. His first mission took him to Kyiv to meet Ukrainian President Volodymyr Zelenskyy and discuss support for the reconstruction of Ukrainian cities.

RUN LEONIE, RUN: As part of her personal farewell to Germany’s €9 national transit system, my colleague Leonie Kijewski set about trying to travel 750 kilometers from Aachen to Germany’s western border with Belgium and the Netherlands up to Görlitz on the Polish border. If you haven’t had the chance yet, I highly recommend his epic tale. In addition, the Association of German Transport Companies published a study this week estimating that, since 10% of train journeys would otherwise have taken place by car, CO2 production was reduced by around 1.8 million tonnes. by the program.

URBAN TRENDS

IS WALLONIA ATTACHED TO CARS? The Brussels region is taking steps to reduce the number of cars on its streets, but just to the south, in the French-speaking region of Wallonia, car culture is still deeply ingrained. My colleague Camille Gijs spoke with Olivier Saint-Amand, the mayor of Enghien, to talk about the challenges to be met in order to change the local mentality towards the car.

Cultural differences: Although the city of 14,000 inhabitants is located on the border between Flanders and Wallonia, its relationship to cycling is resolutely Walloon. “For a young Flemish, taking his bike will seem a bit trendy,” said Saint-Amand, a member of the eco-friendly party Ecolo. This is not the case in Enghien, where until a few years ago, children who went to school by bicycle parked them at a distance to avoid being made fun of by their comrades, he recalls. But while there is still a “cultural problem”, something is changing. Faced with a cost of living crisis, he said people were paying attention to where they could save money and taking bikes for shorter journeys.

The plan: Saint-Amand, as former alderman of Enghien in charge of mobility, drew up the town’s current mobility plan, which aims to promote cycling with designated cycle paths, safe zones around schools and improved routes to the city’s train station. Between 2019 and 2024, the city plans to invest nearly €1.5 million in infrastructure and the promotion of cycling. Some of this money comes from the Walloon regional government’s plan to subsidize bike-friendly infrastructure across the region.

image

The medieval church of Saint-Nicolas de Myre in Enghien is surrounded by a car park | Aitor Hernandez-Morales

Paved Landscape: Saint-Amand acknowledged that the bike-friendly plan is “to the detriment of the car”. Future plans will give more space for pedestrians and cyclists, but local authorities are working on two major parking projects outside the city centre, he said.

Afraid of the unknown: Many residents are hesitant to adopt a new, less car-dependent way of life and worry about how it will change the city, according to Saint-Amand. “Change is scary, for everyone, including me.” But the mayor said he was optimistic that things were moving in the right direction: “There is a change in modality, and with the price of energy, that will only strengthen this movement. Something is happening. Another reason for his optimism: Walloon Mobility Minister Philippe Henry is another member of the green party – which Saint-Amand says would lead to more investment in sustainable transport.

STATISTICS AND THE CITY

PUBLIC FORUM

Last week we asked readers to write to us with suggestions for streets they would like to see pedestrianized.

Janet Kaiser, from Criccieth, Wales, suggested Oxford Street in London and the Champs-Élysées in Paris. In Washington, DC, reader Ned Russell suggested New York’s Pennsylvania Avenue or Park Avenue.

This week we would like to hear about your experiences with the €9 monthly transport ticket in Germany. Whether you live in the countryside or use it when visiting in the summer, what were your impressions? Where did you go and how was your journey? Let me know.

LOCAL LIBRARY

image

The dismantling of a Soviet-era monument in Riga | Kaspar Krafts/AFP via Getty Images

— I was struck by the visuals and the clarity of communication in this video published by the Mayor of Riga, Mārtiņš Staķis, showing the destruction of Soviet monuments in the Latvian capital and explaining how 2.1 million euros will be spent to beautify the parks where they once stood.

— The Ambassador of the Cycling Embassy of the Netherlands, Mark Wagenbuur, has put together a beautiful video decoding the poetry that adorns the walls of a 1,300 meter long stretch of the Beneluxtunnel. Having read it a few weeks ago, I am delighted to finally understand what all these words mean!

— This opinion piece by Cian Ginty in the Irish Cycle points to an interesting trend: Dublin’s successful efforts to reduce car traffic have led to a ‘huge return to city center living’. It also argues that access to sustainable transport is key to the success of housing development strategies.

— Spat on it, abused it and ran off the road. The Guardian’s Helen Pidd has this slick article on why cyclists in the UK have become targets in a nasty culture war.

THANKS TO: Giovanna Coi, Peter O’Brien, Pieter Haeck, Camille Gijs, my editors Esther King and James Randersonand my producer Julia Poloni.

POLITICO’s Global Policy Lab is a collaborative journalism project seeking solutions to the challenges facing modern societies in a time of rapid change. Over the next few months, we’ll be hosting a conversation about how to make cities more livable and sustainable.

More… Aitor Hernandez-Morales

]]>
Germany €9 note – Soviet statues removed – Super fast electric ferries – POLITICO https://mact-asso.org/germany-e9-note-soviet-statues-removed-super-fast-electric-ferries-politico/ Thu, 25 Aug 2022 13:21:38 +0000 https://mact-asso.org/germany-e9-note-soviet-statues-removed-super-fast-electric-ferries-politico/ Press play to listen to this article A conversation about what makes a city livable. By AITOR HERNANDEZ-MORALES Send tips here | Tweeter @aitorehm | View in your browser Happy Thursday, city ​​lovers, and welcome to POLITICO’s Living Cities project. Summer is lazily winding down, and that means we’re saying goodbye to days away from […]]]>

Press play to listen to this article

A conversation about what makes a city livable.

By AITOR HERNANDEZ-MORALES

Send tips here | Tweeter @aitorehm | View in your browser

Happy Thursday, city ​​lovers, and welcome to POLITICO’s Living Cities project.

Summer is lazily winding down, and that means we’re saying goodbye to days away from the office and the beach. We are also about to say tschüß the German national public transport ticket at €9 per month, which since last June has allowed travelers unlimited access to all buses, trams, metros and other local means of transport, as well as to regional trains running on intercity routes at across the country.

As the program draws to a close, many are already wondering: has it achieved its goal of persuading car owners to abandon private vehicles in favor of public transport? Or was it an over-the-top stunt as frivolous as a summer fling?

We dig into it after the jump.

METRO BRIEFING

END OF LINE FOR THE €9 TICKET IN GERMANY: There is no doubt that Germany’s state-subsidised monthly subscription system is extremely popular. Since its launch in June, around 38 million residents and visitors have purchased the tickets which allow users to use local and regional transport for just €9 per month.

Lindner says no: But despite the program’s popularity, there are no plans to extend it beyond its August 31 end date. According to Liberal Finance Minister Christian Lindner, it would be far too costly to extend the initiative, which has been subsidized to the tune of 2.5 billion euros in public treasury. “Nearly free public transport is not something we can afford in the long term,” he said earlier this month.

image

Germany’s €9 note | Ina Fassbender/AFP via Getty Images

So, was it worth it? A full review of the three-month program will not be released by the German Transport Ministry until November, but initial data indicates that the initiative has achieved its basic goals of curbing inflation and alleviating the cost of fuel crisis. life while providing an incentive to motorists. to get rid of their cars.

Railway boost: Germany’s Federal Statistical Office found that a fifth of Germans regularly used public transport for the first time thanks to the €9 ticket; it also found a 42% increase in train travel in June and July compared to the same period before COVID 2019.

Anti inflation: Meanwhile, a study by the Cologne Institute for Economic Research claimed that removing the cost of public transport from household budgets – a monthly pass covering only central Berlin typically costs €86, while ‘in Hamburg it’s €115 – has helped reduce runaway inflation by up to 2 percentage points.

Cleaner air: And researchers from the University of Potsdam said the ticket led to a 6-7% decrease in air pollution levels across Germany – with the greatest effect during the working week and in urban areas.

Auf wiedersehen? If the €9 note is about to disappear, there are already various ideas to resurrect it in different forms. The German Greens are proposing to fund a €29 ticket for unlimited regional transit and a €49 ticket for unlimited travel across the country by scrapping tax breaks for polluting industries. The leader of the Bavarian Christian Social Union, Markus Söder, supports the creation of an annual rail pass at €365. And the Association of German Transport Companies has made its own proposal for a €69 monthly ticket valid across the country, which it says would require an annual public subsidy of €2 billion.

image

From September 1 to December 31, all local and medium-distance travel on Spain’s public railways will be free | Miguel Riopa/AFP via Getty Images

Hasta ahora: While the discounted ticket may soon disappear in Germany, the party is about to begin in Spain. From September 1 to December 31, all local and medium-distance travel on the country’s public railways will be free. The measure follows a Spanish government program to fund a 30% discount on multi-trip tickets for urban transit systems across the country this fall.

Now read this: The full report on the German €9 program and other models from across the EU from my colleagues Joshua Posaner, Wilhemine Preussen and Laurenz Gehrke.

CITY HIGHLIGHTS

I MISSED THE MARK: Copenhagen is backing away from its goal of becoming the world’s first CO2-neutral capital by 2025. According to Mayor Sophie Hæstorp Andersen, the Danish capital has already reduced its CO2 emissions by 80%, but to become completely CO2-neutral it would have to eliminate the emissions generated. by the Amager Resource Center (ARC) incinerator. The ARC recently canceled plans to build a plant to capture the CO2 it emits after determining it was not eligible for funding from the Danish government’s Carbon Capture and Storage (CCS) fund. 8 billion DKK (1.07 billion euros). “It’s a shame we won’t reach it by 2025,” said Hæstorp Andersen. “But that’s not the same as saying we won’t get there by 2026, 2027 or 2028.”

image

The Soviet-era monument in Riga’s Uzvaras Park commemorating the Red Army’s victory over the Nazis in World War II | EyesWideOpen/Getty Images

DISPOSAL OF SOVIET STATUES: This week, Riga began the process of demolishing a Soviet-era statue in the Latvian capital’s Uzvaras Park that commemorates the Red Army’s victory over the Nazis in World War II. Earlier this month, the local government announced plans to demolish the statues and the giant pillar topped with Soviet stars, arguing the monument glorified Latvia’s occupation and Russia’s ongoing war crimes. The move follows the Estonian government’s decision to dismantle a Soviet memorial in Narva, a Russian-speaking town on the Russian border, as part of a wider campaign to remove all Soviet war memorials in public areas.

RISE FROM THE RUINS: The mayors of Florence, Athens, Helsinki, Lyon, Marseille, Oslo, Riga and Tirana traveled to Kyiv this week to sign a political agreement supporting the sustainable reconstruction of Ukrainian cities. The pact, backed by city lobby group Eurocities and the Ukrainian Congress of Local and Regional Authorities, lays the groundwork for collaboration between local leaders across the EU and within Ukraine. Read it here.

MOVE LIKE THE DUTCH: Nearly 700 million tonnes of carbon pollution would be saved each year if every person adopted Dutch levels of bicycle use, according to a new study published in the journal Communications Earth and Environment. Another key point to remember: the main obstacle to increased bicycle adoption in developed countries is the fear “of riding on the road next to motor vehicles”. Install better and safer cycling infrastructure — in other words, go Dutch!

Uber in Brussels: Ride-sharing company Uber told POLITICO it is working to integrate regular Brussels taxis into its platform to comply with new local regulations. This means that Brussels residents and visitors will be able to order a regular taxi via the Uber app, writes Pieter Haeck.

WATER CONCERNS: The Portuguese government has recommended that 43 municipalities temporarily increase water prices for their biggest consumers and suspend street cleaning and the watering of public parks and gardens.

URBAN TRENDS

ELECTRIC TRANSPORTERS: The decarbonisation of ships is a major challenge for European cities bordering on rivers that currently depend on ferries powered by fossil fuels to move residents across wide rivers or bays. In Stockholm, local authorities aim to solve this problem with super-fast electric ferries that will be able to transport passengers from the Swedish capital to the many islands in the immediate vicinity.

image

A rendering of the super-fast electric ferries that will debut in Stockholm next year | Candela

In a partnership with the Swedish Transport Authority, Stockholm-based start-up Candela is developing an electric-powered hydrofoil that produces virtually no wake, which would exempt it from Stockholm’s strict speed limits . The plan is part of Sweden’s ambition to reduce emissions from the transport sector by 70% by 2030.

According to Gustav Hemming, a local legislator in the Stockholm region responsible for ferries, the technology could be a game-changer as it will allow for shorter journeys and zero emissions.

Here’s Charlie Duxbury’s full report on the scheme, which is set to start next spring and run for four years at a cost of around £1.9m.

STATISTICS AND THE CITY

PUBLIC FORUM

I recently became obsessed with animator Jan Kamensky’s Visual Utopias project, through which he creates rendered iconic European thoroughfares with cars magically pulled out and busy roads replaced with cycle lanes, walking paths and gardens.

image

Kamensky’s vision of a greener Karl-Marx-Straße in Berlin | John Kamensky

Our question for you this week: Which famous square or boulevard would you like to see without a car and why? Send me your thoughts here.

LOCAL LIBRARY

— I was fascinated to read about land artist Michael Heizer Town project, a vast complex of outdoor structures and landmasses that has been built over the past 50 years in the Nevada desert; The Art Newspaper ran a story about the mile-long structure, which will open next week.

– Cars dominate adverts at most football stadiums, but this week I was delighted to read that Bundesliga side SC Freiburg, the home team in one of Germany’s greenest cities, reverses this trend. They have made the corporate bike rental group JobRad their exclusive mobility partner. The move aims to underline the team’s “passion for cycling” and motivate fans to travel sustainably.

— In an excellent interview with Mensagem de Lisboa, Ton Salvadó — ​​the man responsible for Barcelona’s first ‘super-islands’ — says that “eliminating cars from cities may be a utopia, but the world is guided by utopias”. In effect.

THANKS TO: Giovanna Coi, Wilhemine Preussen, Joshua Posaner, Laurenz Gehrke, Zia Weise, Pieter Haeck, Charlie Duxbury, my editor James Randersonand my producer Julia Poloni.

POLITICO’s Global Policy Lab is a collaborative journalism project seeking solutions to the challenges facing modern societies in a time of rapid change. Over the next few months, we’ll be hosting a conversation about how to make cities more livable and sustainable.

More… Aitor Hernandez-Morales

]]>
Pfizer requests FDA approval for Omicron-specific booster dose – Consumer Health News https://mact-asso.org/pfizer-requests-fda-approval-for-omicron-specific-booster-dose-consumer-health-news/ Mon, 22 Aug 2022 19:11:07 +0000 https://mact-asso.org/pfizer-requests-fda-approval-for-omicron-specific-booster-dose-consumer-health-news/ MONDAY, Aug. 22, 2022 (HealthDay News) — Pfizer Inc. announced Monday that it has applied to the U.S. Food and Drug Administration for emergency use approval for an updated booster shot that targets multiple versions of the Omicron variant. Animal studies show that the new mRNA vaccine produces an immune response against the BA.4 and […]]]>

MONDAY, Aug. 22, 2022 (HealthDay News) — Pfizer Inc. announced Monday that it has applied to the U.S. Food and Drug Administration for emergency use approval for an updated booster shot that targets multiple versions of the Omicron variant.

Animal studies show that the new mRNA vaccine produces an immune response against the BA.4 and BA.5 subvariants, with clinical trials expected to begin this month, the company said in a press release announcing the application.

“The agility of the mRNA platform, coupled with extensive clinical experience with the Pfizer-BioNTech COVID-19 vaccine, has enabled us to develop, test and manufacture updated, high-quality vaccines that align with strains in circulation at an unprecedented rate,” Pfizer said. Chairman and CEO Albert Bourla.

“Having ramped up production rapidly, we are able to immediately begin distribution of Omicron BA.4/BA.5 bivalent boosters, if approved, to help protect individuals and families as we prepare for power surges. fall and winter potentials,” he said in The Release.

The BA.5 subvariant accounts for nearly 90% of new COVID cases in the United States, according to the United States Centers for Disease Control and Prevention.

The FDA plans to review the data in September. If authorized, the vaccine can be distributed immediately, BNC News reported.

Harvard epidemiologist Bill Hanage said BNC News that the turnaround time for this new vaccine was “remarkably fast”. Vaccines typically take years to develop and distribute, and the latest Omicron subvariants only began to spread widely in the United States in early June.

The new vaccine will be “important” especially for people vulnerable to serious infections, such as the elderly, Hanage said.

The new vaccines should be available before an expected winter surge of COVID cases, White House COVID coordinator Dr. Ashish Jha said last week.

FDA allows Pfizer to submit less vaccine data than for other COVID vaccines because modified vaccines that target emerging strains of COVID can be approved without lengthy clinical trials, BNC News reported.

More information

Visit the US Centers for Disease Control and Prevention to learn more about COVID vaccines.

SOURCES: Pfizer, press release, August 22, 2022; BNC News

From articles on your site

Related articles on the web

]]>
LIVE Marseille vs Nantes & More Latest News Here https://mact-asso.org/live-marseille-vs-nantes-more-latest-news-here/ Sat, 20 Aug 2022 19:50:59 +0000 https://mact-asso.org/live-marseille-vs-nantes-more-latest-news-here/ League 1 Alexis Sánchez makes his debut as a Marseille white as a starter at the Stade Vélodrome, Maravilla’s first game as a star at OM. By Milan Vrsalovic 08/20/2022 – 3:50 p.m. CLT 08/20/2022 – 3:50 p.m. CLT © Getty ImagesSánchez will play his second Ligue 1 game in France, the first as a […]]]>

League 1

Alexis Sánchez makes his debut as a Marseille white as a starter at the Stade Vélodrome, Maravilla’s first game as a star at OM.

Sánchez will play his second Ligue 1 game in France, the first as a starter.
© Getty ImagesSánchez will play his second Ligue 1 game in France, the first as a starter.

important day for Olympic Marseille that at home at the Stade Vélodrome will be played a great match for the third date of Ligue 1 in France with Nanteswith the good news that Alexis Sanchez will add his first minutes as a starter in Marseille.

The Wonder already played tied with Brestois passing through and now it will be his first game as a local, which ensures a great reception from the Olympics fans and similar to what he was his arrival at Marseille airport a week ago.

Although in the last hours the first doubts about the participation of Alexis were sown, since they reported that he was not in training on Thursdaythis Friday, his presence was confirmed in the situation and it was already announced that he would start leading the attack of his new club.

The Chilean national team’s top scorer team got off to a great start by beating Reims in the first fixture, but with the draw the following day, he left PSG as the only scorer in the French championship. There is little margin with the Parisian stars, so Marseille must win this Saturday against Nantes, a big cast 2021-22 and who have just disputed the Super Cup with Paris Saint-Germain themselves.

Minute by minute:

Day and time: When does Alexis Sánchez’s Marseille play against Nantes?

Olympique de Marseille vs Nantes play this Saturday August 20 at 3 p.m. in Chile.

Online: Where to watch Alexis Sánchez’s Marseille live stream?

If you are looking for a link to watch Alexis Sánchez’s Marseille live, you can watch the match live on Star+.

LIVE Marseille-Nantes
& Latest News Update

I tried to give all kinds of news to y’all latest news today 2022 through this site and you will like all this news very much because all the news that we always give in this news is always there. It’s on a trending topic and regardless of the latest news

it was always our effort to reach you that you continue to get the Electricity News, Degree News, Donation News, Bitcoin News, Trade News, Real Estate News, Gaming News, Trending News, Digital Marketing, Telecom News, Beauty News, Banking News, Travel News, Health New, Cryptocurrency News, Claims News the latest news and you always keep getting the news information for free through us and also tell people. Give that any information related to other types of news will be

LIVE Marseille-Nantes
and more live news

All this news i made and shared for you, you will like it very much and we keep bringing you topics like every time so you keep getting hot news like trending topics and you It’s our goal to be able to have

all kinds of news without going through us so that we can reach you the latest and best news for free so that you can go further by getting the information of this news with you. Later we will continue

to provide information on more world news update today types of latest news through posts on our website so that you always keep moving forward in this news and whatever type of information will be there, it will definitely be passed on to you.

LIVE Marseille-Nantes
and more news today

All this news that I have brought you or will be the most different and best news that you will not get anywhere, as well as the information Trending News, Latest News, Health News, Science News, Sports News, Entertainment News, Technology News, Business News, World News of this made available to you all so that you are always connected with the news, stay ahead of the game and continue to today’s news all types of news for free till today so you can get the news by getting it. Always take two steps forward

Credit goes to news website – This news website from the original content owner. This is not my content so if you want to read the original content you can follow the links below

Get original links here🡽

]]>